Skip to main content

Advertisement

SpringerLink
Log in

Assessment of Serum MicroRNA-21 Gene Expression for Diagnosis and Prognosis of Colorectal Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

MicroRNAs (miRNAs) are small, non-coding RNAs that are involved in carcinogenesis through posttranscriptional gene regulatory activity. The current study aimed to evaluate serum miR-21 expression levels as potential biomarkers for diagnosis and prognosis of colorectal cancer (CRC) patients.

Methods

Quantitative real-time RT-PCR was applied to determine the relative expression level of miR-21 in serum. At the same time, the sensitivity and specificity of this marker were evaluated by receiver operating characteristic (ROC) curve analysis.

Results

miR-21 expression levels of serum were 3.4 and 1.25 in patient and control, respectively (p < 0.05). The sensitivity and specificity of miR-21 were found to be 95.8% and 91.7%, respectively. The high expression level of serum miR-21 were associated with higher local recurrence, TNM staging, PT staging, venous invasion, liver metastasis, and recurrence (p < 0.05).

Conclusion

The results of this study indicated that miR-21 expression levels in serum can be considered as a novel non-invasive biomarker for early detection and prognosis of CRC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(74–108):3.

    Google Scholar 

  2. El-Bolkainy TN, ASakr M, Nouh AA, El-Din NH. A comparative study of rectal and colonic carcinoma: demographic, pathologic and TNM staging analysis journal of the Egyptian. Natl Cancer Inst. 2006;18:258–63.

    Google Scholar 

  3. Mastalier B, Botezatu C. Colentina surgical clinic experience in treatment of rectal cancer. Romanian statistical review - supliment trimestrul II. 2012:126–34.

  4. Minna J, Schiller JH (2008): Harrison’s principles of internal medicine. New York: McGraw-Hill, 285(16): 12011–12027.

    Google Scholar 

  5. Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1975–2011. Bethesda: National Cancer Institute; 2014. p. 2014.

    Google Scholar 

  6. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol. 2009;104:739–50.

    Article  Google Scholar 

  7. Qaseem A, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156:378–86.

    Article  Google Scholar 

  8. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–95.

    Article  CAS  Google Scholar 

  9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J M. 1993;328:1365–71.

    Article  CAS  Google Scholar 

  10. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.

    Article  CAS  Google Scholar 

  11. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer.What you should know. Oncology (Williston Park). 2006;20:579–87.

    Google Scholar 

  12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  CAS  Google Scholar 

  13. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.

    Article  CAS  Google Scholar 

  14. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer. 2007;43:1529–44.

    Article  CAS  Google Scholar 

  15. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.

    Article  CAS  Google Scholar 

  16. Chevillet JR, Lee I, Briggs HA, He Y, Wang K. Issues and prospects of microRNA-based biomarkers in blood and other body fluids. Molecules. 2014;19:6080–105.

    Article  Google Scholar 

  17. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256:544–51.

    Article  Google Scholar 

  18. Mishra PJ. Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2014;14:917–9.

    Article  CAS  Google Scholar 

  19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.

    Article  CAS  Google Scholar 

  20. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6:e20769.

    Article  CAS  Google Scholar 

  21. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biol. 2013;34(4):2175–81.

    Article  CAS  Google Scholar 

  22. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130(9):2077–87.

    Article  CAS  Google Scholar 

  23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.

    Article  CAS  Google Scholar 

  24. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.

    Article  Google Scholar 

  25. Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test? Dig Dis Sci. 2015;60(3):664–71.

    Article  Google Scholar 

  26. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.

    Article  CAS  Google Scholar 

  27. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013;329(2):125–36.

    Article  CAS  Google Scholar 

  28. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26.

    Article  CAS  Google Scholar 

  29. Bastaminejad S, Taherikalani M, Ghanbari R, Akbari A, Shabab N, Saidijam M. Investigation of microRNA-21 expression levels in serum and stool as a potential non-invasive biomarker for diagnosis of colorectal cancer. Iran Biomed J. 2016;21:106–13.

    PubMed  Google Scholar 

  30. Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, et al. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther. 2016;23:246–53.

    Article  CAS  Google Scholar 

  31. Almeida AL, Bernardes MV, Feitosa MR, Peria FM, Tirapelli DP, Rocha JJ, et al. Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer. Acta Cir Bras. 2016;31:13–8.

    Article  Google Scholar 

  32. Montagnana M, Benati M, Danese E, Minicozzi AM, Paviati E, Gusella M, et al. (2016): plasma expression levels of circulating miR-21 are not useful for diagnosing and monitoring colorectal cancer. Clin Lab. 2016;62:967–70.

    Article  CAS  Google Scholar 

  33. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM, et al. Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol. 2013;108:369–73.

    Article  CAS  Google Scholar 

  34. Xi Y, Shalgi R, Fodstad O, et al. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res. 2006;12:2014–24.

    Article  CAS  Google Scholar 

  35. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143m and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72:397–402.

    Article  CAS  Google Scholar 

  36. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez MLA, et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One. 2011;6:e16979.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Amal F. Ghareib, Randa H. Mohamed & Sara F. Saadawy

  2. Clinical Laboratory Department, Faculty of Applied Medical Science, Taif University, Taif, Saudi Arabia

    Amal F. Ghareib

  3. General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Ahmed R. Abd el-Fatah

Authors
  1. Amal F. Ghareib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randa H. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed R. Abd el-Fatah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara F. Saadawy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Randa H. Mohamed.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghareib, A.F., Mohamed, R.H., Abd el-Fatah, A.R. et al. Assessment of Serum MicroRNA-21 Gene Expression for Diagnosis and Prognosis of Colorectal Cancer. J Gastrointest Canc 51, 818–823 (2020). https://doi.org/10.1007/s12029-019-00306-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-019-00306-w

Keywords

Search

Navigation